Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Authors:
- Michael BöhmMBMichael Böhm
- Stefan AnkerStefan Anker
- Felix MahfoudFMFelix Mahfoud
- Lucas LauderLLLucas Lauder
- Gerasimos FilippatosGFGerasimos Filippatos
- João Pedro FerreiraJFJoão Pedro Ferreira
- Stuart J PocockSPStuart J Pocock
- Martina BrueckmannMBMartina Brueckmann
- Christoph WannerCWChristoph Wanner
- Faiez ZannadFZFaiez Zannad
Open Access
- 7 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (5) , 396-407
Abstract
Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects. The association of SBP and the treatment effects of empagliflozin in EMPEROR-Preserved (empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction) was evaluated. Randomized patients (n = 5988) were grouped according to SBP at baseline ( 130 mmHg, n = 3118). The effect of empagliflozin on blood pressure, cardiovascular death or HF hospitalization (primary outcome), total HF hospitalizations, and rate of decline in estimated glomerular filtration rate was studied. Over a median of 26.2 months, the placebo-corrected decline was small and not significantly different across baseline SBP. On placebo, the risk of cardiovascular death or hospitalization for HF was 8.58 at >130 mmHg, 8.26 at 110–130 mmHg, and 11.59 events per 100 patient-years at 130 mmHg, P = 0.08 vs. 110–130 mmHg). There was no evidence for baseline SBP moderating the effect of empagliflozin on risk of HF events (primary endpoint interaction P = 0.69, recurrent HF hospitalizations interaction P = 0.55). When comparing empagliflozin with placebo, SBP did not meaningfully associate with adverse events such as hypotension, volume depletion, and acute renal failure. In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozin’s treatment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit. URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951 Effect of empagliflozin on blood pressure and outcomes. Effect of empagliflozin on systolic blood pressure (SBP) according to baseline SBP (top), effect of Empa on the primary outcome over the spectrum of baseline SBP (middle), and effect of Empa on the slope of change in estimated glomerular filtration rate (adjusted mean difference, mL/min/1.73 m2/year) (bottom).Keywords
This publication has 22 references indexed in Scilit:
- Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HFEuropean Heart Journal, 2017
- Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort studyThe Lancet, 2016
- Characterization of Subgroups of Heart Failure Patients with Preserved Ejection Fraction with Possible Implications for Prognosis and Treatment ResponseEuropean Journal of Heart Failure, 2015
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and HypertensionDiabetes Care, 2014
- Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure According to Blood Pressure Level in SHIFTEuropean Journal of Heart Failure, 2014
- Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HFClinical Research in Cardiology, 2014
- Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trialAmerican Heart Journal, 2013
- Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiencyEuropean Heart Journal, 2012
- Epidemiology and Clinical Course of Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2011
- Effect of Intensive Versus Standard Blood Pressure Lowering on Diastolic Function in Patients With Uncontrolled Hypertension and Diastolic DysfunctionHypertension, 2010